3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
73
Active not recruiting
49
Recruiting
35
Unknown
27
Terminated
19
Not yet recruiting
9
Withdrawn
4
Enrolling by invitation
1
Sponsor Class
UNKNOWN
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
1
Interventions
zilucoplan
1
rozanolixizumab
1
fludarabine phosphate
1
fludarabine
1
exemestane
1
epigallocatechin gallate
1
durvalumab
1
aumolertinib
1
atropine sulfate-diphenoxylate hydrochloride drug combination
1
Vincristine
1
Tamoxifen
1
Sodium Chloride
1
R-CHOP protocol
1
Prednisone
1
Pemetrexed
1
Omeprazole
1
Melphalan
1
Loperamide
1
Letrozole
1
High-Energy Shock Waves
1
Gastroscopy
1
Etoposide
1
Doxorubicin
1
Dexamethasone
1
Decitabine
1
Cytarabine
1
Cyclophosphamide
1
Cisplatin
1
Catechin
1
Carboplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Enrolling by invitation
×
Pemetrexed
×
Clear all
NCT04762459
2022-02-24
APEX
ChineseAMS
Phase 3
Enrolling by invitation
606 enrolled